Department of Pharmacy and Biotechnology , Alma Mater Studiorum - University of Bologna , Via Belmeloro 6 , Bologna 40126 , Italy.
Department of Cellular, Molecular and Developmental Neurobiology , Cajal Institute, Consejo Superior de Investigaciones Científicas (CSIC) , Av. Doctor Arce, 37 , Madrid 28002 , Spain.
ACS Chem Neurosci. 2019 Jan 16;10(1):279-294. doi: 10.1021/acschemneuro.8b00242. Epub 2018 Oct 9.
Overcoming the lack of effective treatments and the continuous clinical trial failures in neurodegenerative drug discovery might require a shift from the prevailing paradigm targeting pathogenesis to the one targeting simultaneously neuroprotection and neuroregeneration. In the studies reported herein, we sought to identify small molecules that might exert neuroprotective and neuroregenerative potential as tools against neurodegenerative diseases. In doing so, we started from the reported neuroprotective/neuroregenerative mechanisms of psychotropic drugs featuring a tricyclic alkylamine scaffold. Thus, we designed a focused-chemical library of 36 entries aimed at exploring the structural requirements for efficient neuroprotective/neuroregenerative cellular activity, without the manifestation of toxicity. To this aim, we developed a synthetic protocol, which overcame the limited applicability of previously reported procedures. Next, we evaluated the synthesized compounds through a phenotypic screening pipeline, based on primary neuronal systems. Phenothiazine 2Bc showed improved neuroregenerative and neuroprotective properties with respect to reference drug desipramine (2Aa). Importantly, we have also shown that 2Bc outperformed currently available drugs in cell models of Alzheimer's and Parkinson's diseases and attenuates microglial activation by reducing iNOS expression.
克服神经退行性疾病药物发现中缺乏有效治疗方法和持续临床试验失败的问题,可能需要从针对发病机制的现有范式转变为同时针对神经保护和神经再生的范式。在本文报告的研究中,我们试图确定可能具有神经保护和神经再生潜力的小分子,作为对抗神经退行性疾病的工具。为此,我们从具有三环烷基胺支架的精神药物的报道的神经保护/神经再生机制出发。因此,我们设计了一个包含 36 个化合物的重点化学文库,旨在探索有效神经保护/神经再生细胞活性的结构要求,而不会表现出毒性。为此,我们开发了一种合成方案,克服了以前报道的程序的有限适用性。接下来,我们通过基于原代神经元系统的表型筛选管道评估了合成化合物。吩噻嗪 2Bc 相对于参比药物去甲丙咪嗪 (2Aa) 显示出改善的神经再生和神经保护特性。重要的是,我们还表明,2Bc 在阿尔茨海默病和帕金森病的细胞模型中优于现有药物,并通过降低 iNOS 表达来减轻小胶质细胞的激活。